These findings point to the underlying mechanism for the therapeutic effects of CP-MSCs in chronic liver diseases, and may help the development of novel diagnostic and therapeutic approaches to prevent and treat liver fibrosis. The gene discussed is CP; the disease is Hepatic fibrosis.